Bicara Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler analyst Kelsey Goodwin initiated coverage of Bicara Therapeutics (BCAX) with an Overweight rating and $36 price target The firm’s channel checks highlighted a favorable view on Bicara’s patient selection strategy for the pivotal FORTIFi-HN01, ficera’s potentially differentiated mDOR, the importance of continued follow-up in relapsed metastatic head and neck squamous cell cancer, and the overall perception that the large market will likely be split longer term, the analyst tells investors in a research note. Piper sees the recent pullback as offering a highly attractive entry point.